Alejandra Gámez

Alejandra Gámez

Auto-generated profile, based on publicly available information

Alejandra Gámez

Centro de Diagnóstico de Enfermedades Moleculares, Centro de Biología Molecular-SO UAM-CSIC, Universidad Autónoma de Madrid, Campus de Cantoblanco, 28049 Madrid/Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Investigación Sanitaria IdiPAZ, Madrid, Spain

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HEHeidi Erlandsen
Heidi Erlandsen
Angel L. PeyAngel L. Pey
Angel L. Pey
AGAlejandra Gámez
Alejandra Gámez
BPBelén Pérez
Belén Pérez
LDLourdes R. Desviat
Lourdes R. Desviat
RSRaymond Charles Stevens
Raymond Charles Stevens
Phenylketonuria patients harboring a subset of phenylalanine hydroxylase (PAH) mutations have recently shown normalization of blood phenylalanine levels upon oral administration of the PAH cofactor tetrahydrobiopterin [(6 R )- l - erythro -5,6,7,8-tetrahydrobiopterin (BH 4 )]. Several hypotheses have been put forward to explain BH 4 responsiveness, but the molecular basis for the corrective effect(s) of BH 4 has not been understood. We have investigated the biochemical, kinetic, and structural changes associated with BH 4 -responsive mutations (F39L, I65T, R68S, H170D, E178G, V190A, R261Q, A300S, L308F, A313T, A373T, V388M, E390G, P407S, and Y414C). The biochemical and kinetic characterization of the 15 mutants studied points toward a multifactorial basis for the BH 4 responsiveness; the mutants show residual activity (>30% of WT) and display various kinetic defects, including increased K m (BH 4 ) and reduced cooperativity of substrate binding, but no decoupling of cofactor (BH 4 ) oxidation. For some, BH 4 seems to function through stabilization and protection of the enzyme from inactivation and proteolytic degradation. In the crystal structures of a phenylketonuria mutant, A313T, minor changes were seen when compared with the WT PAH structures, consistent with the mild effects the mutant has upon activity of the enzyme both in vitro and in vivo . Truncations made in the A313T mutant PAH form revealed that the N and C termini of the enzyme influence active site binding. Of fundamental importance is the observation that BH 4 appears to increase Phe catabolism if at least one of the two heterozygous mutations has any residual activity remaining.

19 March 2003 in Human Mutation
Verified
Journal Article
Open access
PDF file
Angel L. PeyAngel L. Pey
Angel L. Pey
LDLourdes R. Desviat
Lourdes R. Desviat
AGAlejandra Gámez
Alejandra Gámez
MUMagdalena Ugarte
Magdalena Ugarte
BPBelén Pérez
Belén Pérez
When analyzed in the context of the phenylalanine hydroxylase (PAH) three‐dimensional structure, only a minority of the PKU mutations described world‐wide affect catalytic residues. Consistent with these observations, recent data point to defective folding and subsequent aggregation/degradation as a predominant disease mechanism for several mutations. In this work, we use a combined approach of expression in eukaryotic cells at different temperatures and a prokaryotic system with co‐expression of chaperonins to elucidate and confirm structural consequences for 18 PKU mutations. Three mutations are located in the amino terminal regulatory domain and 15 in the catalytic domain. Four mutations were found to abolish the specific activity in all conditions. Two are catalytic mutations (Y277D and E280K) and two are severe structural defects (IVS10–11G>A and L311P). All the remaining mutations (D59Y, I65T, E76G, P122Q, R158Q, G218V, R243Q, P244L, R252W, R261Q, A309V, R408Q, R408W, and Y414C) are folding defects causing reduced stability and accelerated degradation, although some of them probably affect residues involved in regulation. In these cases, we have demonstrated that the amount of mutant PAH protein and residual activity could be modulated by in vitro experimental conditions, and therefore the observed in vivo metabolic variation may be explained by interindividual variation in the quality control systems. The results derived provide an experimental framework to define the mutation severity relating genotype to phenotype. They also explain the observed inconsistencies for some mutations in patients with similar genotype and different phenotypes. Hum Mutat 21:370–378, 2003.

30 September 2004 in Human Mutation
Verified
Journal Article
Closed access
PDF file
Angel L. PeyAngel L. Pey
Angel L. Pey
BPBelén Pérez
Belén Pérez
LDLourdes R. Desviat
Lourdes R. Desviat
MGMaría Ángeles Martínez García
María Ángeles Martínez García
CACristina Aguado
Cristina Aguado
AMAurora Martinez
Aurora Martinez

30 December 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CSChristineh N. Sarkissian
Christineh N. Sarkissian
AGAlejandra Gámez
Alejandra Gámez
LWLin Wang
Lin Wang
MCMarilyse Charbonneau
Marilyse Charbonneau
PFPaul Fitzpatrick
Paul Fitzpatrick
CSCharles R. Scriver
Charles R. Scriver
Phenylketonuria (PKU) is a metabolic disorder, in which loss of phenylalanine hydroxylase activity results in neurotoxic levels of phenylalanine. We used the Pah enu2/enu2 PKU mouse model in short- and long-term studies of enzyme substitution therapy with PEGylated phenylalanine ammonia lyase (PEG-PAL conjugates) from 4 different species. The most therapeutically effective PAL ( Av, Anabaena variabilis ) species was one without the highest specific activity, but with the highest stability; indicating the importance of protein stability in the development of effective protein therapeutics. A PEG- Av -p.C503S/p.C565S-PAL effectively lowered phenylalanine levels in both vascular space and brain tissue over a >90 day trial period, resulting in reduced manifestations associated with PKU, including reversal of PKU-associated hypopigmentation and enhanced animal health. Phenylalanine reduction occurred in a dose- and loading-dependent manner, and PEGylation reduced the neutralizing immune response to the enzyme. Human clinical trials with PEG- Av -p.C503S/p.C565S-PAL as a treatment for PKU are underway.

1 July 2008 in Journal of Molecular Biology
Verified
Journal Article
Closed access
LWLin Wang
Lin Wang
AGAlejandra Gamez
Alejandra Gamez
HAHolly Archer
Holly Archer
EAEnrique E. Abola
Enrique E. Abola
CSChristineh N. Sarkissian
Christineh N. Sarkissian
RSRaymond Charles Stevens
Raymond Charles Stevens

1 December 2005 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
CSChristineh N. Sarkissian
Christineh N. Sarkissian
AGAlejandra Gámez
Alejandra Gámez